The list of benefits tied to GLP-1 medications that go beyond weight loss keeps growing, and the latest addition might be the most reassuring one yet for anyone who’s worried about what rapid weight loss does to their bones.
A new analysis presented at ENDO 2026, the Endocrine Society’s annual meeting, found that adults with type 2 diabetes taking semaglutide had about 15% fewer bone fractures than people taking other anti-obesity medications.
Nearly 60,000 Records, One Clear Gap
Researchers from Stanford, led by Dr. Jairo Noreña, pulled records from a massive electronic health database covering 161 million patients across U.S. hospitals and academic medical centers. From that pool, they identified nearly 60,000 adults with type 2 diabetes who had no prior history of fractures or osteoporosis medication use.
About 26,000 of them were on semaglutide. The other roughly 33,000 were on a different anti-obesity medication, dulaglutide, phentermine/topiramate, or bupropion/naltrexone, with no semaglutide use of their own. From there, the researchers simply tracked what happened to each group’s bones.
The Numbers
The semaglutide group came out ahead: 794 fractures compared to 1,045 in the comparison group. That gap alone would be interesting. But what makes it truly notable is a detail that runs against what you’d expect. The semaglutide group also lost more weight than the comparison group.
That matters because substantial weight loss is typically linked to greater bone loss. It’s one of the most common concerns raised about GLP-1s, especially at the pace these drugs tend to produce results. This is one of the first major pieces of data suggesting that concern may not hold up the way people assumed.
What Makes This Surprising
To be clear about what this study is and isn’t, this doesn’t mean weight loss and bone loss are unrelated. Prior research has shown that rapid weight loss with GLP-1s can come with thinner bones, while slower, more moderate weight loss tends to preserve bone mass better. That relationship isn’t erased here.
What this data suggests is something more specific. Semaglutide may carry less fracture risk than other anti-obesity medications, despite outperforming them on the scale. Losing more weight didn’t translate into losing more bone health, at least in this comparison.
My Own Approach
There’s a real, practical takeaway hiding in that nuance, and this is where I’ll speak from experience rather than just the data. Bone health on any weight-loss journey isn’t something you get to leave entirely up to the medication, GLP-1 or otherwise.
When I started on a GLP-1 medication, I made resistance training a non-negotiable part of my routine from day one, specifically because of this exact concern. I’ll be honest that the smart scale I use to track muscle and bone mass isn’t a clinical-grade tool and shouldn’t be treated as one, but even accounting for that, it’s shown a clear upward trend in both muscle and bone mass over the course of my own journey.
Whatever a medication is doing on its own, giving your body a reason to hold onto bone and muscle through resistance training is a lever YOU actually control directly.
Putting It Into Perspective
Now, of course, we have to keep in mind this was a retrospective, observational analysis. That means it shows an association, not proof of cause and effect.
Dr. Noreña and his team made it clear that prospective, controlled studies still need to happen to confirm the finding. There could be differences between who gets prescribed semaglutide versus the comparison medications that this kind of study design can’t fully rule out.
Worth Watching
This is a tantalizing finding, and one worth watching as more research comes in. Bone fractures aren’t a minor inconvenience, they’re painful, expensive, and can seriously derail someone’s quality of life, especially as we get older.
Finding early evidence that one of the most effective weight-loss medications available might also be the gentlest one on your skeleton is the kind of thing that deserves attention.
